Richard Rudick, MD

Surgeon:

No

Treats:

Adults Only

Richard A. Rudick, MD, is currently Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, the Hazel Prior Hostetler Chair of Neurology, Director of the Mellen Center for Multiple Sclerosis Treatment and Research, and Vice Chairman of Research and Development in the Neurological Institute at Cleveland Clinic.

Dr. Rudick graduated from Case Western Reserve University School of Medicine in 1975. Following internship and residency in medicine at the University of Connecticut, Dr. Rudick trained in neurology at the University of Rochester. During a postdoctoral research fellowship in the Center for Brain Research at the University of Rochester, studies focused on neurologic consequences of immune complex disease in animal systems and immunologic abnormalities in multiple sclerosis (MS) patients. Dr. Rudick’s subsequent studies on cerebrospinal fluid in MS were supported by an NIH clinical investigator career development award.

Dr. Rudick became Director of the Mellen Center in 1987. He has played key roles in several MS clinical trials, including pivotal registration trials of IFNß-1a (Avonex) and natalizumab (Tysabri) for relapsing-remitting MS. He continues studies on immunologic changes in MS patients, has led development of new clinical and imaging measures for MS trials and maintains a consultative clinical practice at the Mellen Center. Dr. Rudick has maintained continuous competitive grant funding from the NIH and the National Multiple Sclerosis Society for over 25 years.

Dr. Rudick established the Office of Clinical Research at Cleveland Clinic in 2001, and was the founding Chairman of the Division of Clinical Research in 2003. In that role, Dr. Rudick established a new General Clinical Research Center at Cleveland Clinic, secured a large Roadmap Clinical Research Training Program award from NIH (the Roadmap K12 Program), led a multidisciplinary effort to secure accreditation of the Cleveland Clinic Human Subjects Protection Program, and provided oversight for expansion of patient-based clinical and translational research. Dr. Rudick played a pivotal role in securing a Clinical and Translational Sciences Award from the NIH, serving as the CTSA Co-Principal Investigator. The CWRU/Cleveland Clinic CTSA created an academic home for clinical and translational research and city-wide infrastructure to support patient-based research.

• Vice Chairman, Research and Development, Neurological Institute, 2007-Present
• Director, Mellen Center for Multiple Sclerosis Treatment and Research, and Hazel Prior Hostetler Professor of Neurology, 1987-Present
• Chairman, Division of Clinical Research, Cleveland Clinic, 2003-2007
• Co-Principal Investigator, Case Western Reserve University/Cleveland Clinic CTSA, 2000-Present
• Principal Investigator, Cleveland Multidisciplinary Clinical Research Training Program (Roadmap K12 Program), 2004-Present

Residency - University of Rochester-Strong Memorial Hospital

Neurology
Rochester, NY USA
1980

Residency - University of Connecticut School of Medicine

Internal Medicine
Farmington, CT USA
1977

Medical School - Case Western Reserve University School of Medicine

Cleveland, OH USA
1975

Undergraduate - Ohio University

Athens, OH USA
1971

• Neurology
• Internal Medicine

Multiple Sclerosis, Neuroimmunology

• Alpha Omega Alpha Honorary Medical Society, elected as a Junior Student, Case Western Reserve University School of Medicine, 1974
• Outstanding Alumnus of the Year Award, Ohio University College of Arts and Sciences, 1994
• Bruce Hubbard Stewart Award for Humanistic Medicine, Cleveland Clinic, 1995
• Hazel Prior Hostetler Professor of Neurology, Cleveland Clinic, 1996
• Alumnus of the Year Award, Department of Neurology, University of Rochester, 1998
• Innovation Award for Brain Parenchymal Fraction Software, Enterprise Development, Inc., 2000
• Arnold and Geri King Lifetime Achievement Award, National Multiple Sclerosis Society, 2002
• Health Care Professional Hall of Fame Award, National Multiple Sclerosis Society, 2003
• Continuously funded by the National Institutes of Health (NINDS, NCRR) and the National MS Society, 1981-Present
• National Center for Research Resources (NIH) Council, 2006-Present
• Council of Councils Member (NIH Director's Office), 2007-Present

• American Academy of Neurology
• American Neurological Association
• American Association for the Advancement of Science (Fellow)
• American Association of Physicians
• Alpha Omega Alpha Honorary Medical Society

• Consultation and Long-term Care
• Consultation On Medical And Epidemiological Research Design And Analysis.

• Acute Disseminated Encephalomyelitis (ADEM)
• Central Nervous System Complications of Autoimmune Disease
• Devic's Disease (Neuromyelitis Optica)
• Multiple Sclerosis
• Neuroimmunology
• Transverse Myelitis

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 12/4/2012, Dr. Rudick has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Rudick receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

• Biogen Idec, Inc.
• Novartis International, AG

Charity. Dr. Rudick has consulted for the following companies but instructed them to donate all compensation directly to one or more non-profit organizations:

• Genzyme Corporation

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

• English